RHHBY : Summary for ROCHE HLDG LTD SPONS - Yahoo Finance

U.S. Markets open in 2 hrs 49 mins

Roche Holding AG (RHHBY)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
32.20-0.21 (-0.64%)
At close: 3:59PM EDT
People also watch
NVSSNYNSRGYAZNBAYRY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close32.41
Open32.13
Bid0.00 x
Ask0.00 x
Day's Range32.07 - 32.44
52 Week Range25.25 - 33.77
Volume1,910,184
Avg. Volume1,160,790
Market Cap217.28B
Beta0.51
PE Ratio (TTM)23.26
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.02 (3.17%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters12 minutes ago

    India watchdog orders antitrust probe into Roche cancer drug

    India's antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients. Trastuzumab has been a mainstay of Roche's profit for years and brought in global sales of about $6.7 billion in 2016, but it has been challenged in the last three years by biosimilars which are sold at about a 25 percent discount to the original. India's Biocon and U.S. firm Mylan, which together sell biosimilars of the drug in over a dozen countries including India, filed a complaint with the Competition Commission of India (CCI) last year alleging Roche misled doctors and regulators to thwart competition to trastuzumab.

  • TheStreet.com2 hours ago

    Roche Tops the Swiss Market After First Quarter Sales Beat Expectations

    Sales rose 4% and were 2% ahead of expectation on strong sales from core drugs and promising results from new treatments.

  • Business Wireyesterday

    New Data at AAN Reinforce Clinical Benefit of Genentech’s OCREVUS (Ocrelizumab) for Relapsing and Primary Progressive Multiple Sclerosis

    Genentech, a member of the Roche Group , announced today that new data from the OCREVUS™ clinical trial programs will be presented during the 69th American Academy of Neurology Annual Meeting in Boston, Massachusetts.